NasdaqGS:DYNBiotechs
Dyne Therapeutics Edges Toward Commercial Stage In High Value Rare Diseases
Dyne Therapeutics (NasdaqGS:DYN) is preparing a U.S. Accelerated Approval submission for z-rostudirsen in Duchenne muscular dystrophy.
The company is also gearing up for a Phase 3 trial of z-basivarsen in myotonic dystrophy.
Dyne is scaling its operations and expanding its development pipeline to support potential commercialization.
Dyne Therapeutics focuses on neuromuscular disease therapies, an area where treatment options remain limited and unmet medical need is high. As z-rostudirsen...